Safety and Effectiveness of Lamivudine When Given Once a Day Versus Twice a Day in Combination With Other Anti-HIV Drugs in HIV-Infected Adults Who Have Never Received Anti-HIV Drugs

This study has been completed.

First Received: March 2, 2000 Last Updated: June 23, 2005 History of Changes

Sponsor:	Glaxo Wellcome
Information provided by:	NIH AIDS Clinical Trials Information Service
ClinicalTrials.gov Identifier:	NCT00004852

Purpose

The purpose of this study is to look at the safety and effectiveness of receiving lamivudine (3TC) once a day versus twice a day as part of an anti-HIV drug combination.

Condition	Intervention	Phase
HIV Infections	Drug: Efavirenz Drug: Lamivudine Drug: Zidovudine	Phase II

Study Type:	Interventional
Study Design:	Treatment, Double-Blind, Safety Study
Official Title:	A Phase II/III 48-Week, Randomized, Double-Blind, Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Lamivudine 300mg Once Daily Vs. Lamivudine 150mg BID in Combination With Zidovudine 300mg BID and Efavirenz 600mg Once Daily in Antiretroviral-Naive Adults With HIV-1 Infection

Resource links provided by NLM:

MedlinePlus related topics: AIDS AIDS Medicines

Drug Information available for: Zidovudine Lamivudine Efavirenz

U.S. FDA Resources

Further study details as provided by NIH AIDS Clinical Trials Information Service:

Study Start Date:

September 1999

Detailed Description:

Patients are randomized to receive the same total dosage of 3TC either twice a day (Group 1) or once a day (Group 2) in combination with ZDV and EFV over 48 weeks. Viral load measurements will be performed at Weeks 4, 8, 12, 16, 20, 24, and every 8 weeks thereafter.

Eligibility

Ages Eligible for Study:	18 Years and older
Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	No

Criteria

Inclusion Criteria

Patients may be eligible for this study if they:

Are 18 years of age or older.
Are HIV-positive.
Have a viral load (level of HIV in the blood) of at least 400 copies/ml within 21 days of study entry.
Have a CD4 count greater than 100 cells/mm3 within 21 days of study entry.
Agree to practice abstinence or use effective barrier methods of birth control (or, if patient is a woman, unable to have children).

Exclusion Criteria

Patients will not be eligible for this study if they:

Have taken any antiretroviral (anti-HIV) agent.
Are pregnant or breast-feeding.
Are unable to absorb food or have trouble taking medicines by mouth.
Abuse alcohol or drugs to an extent that may make study participation difficult.
Are not likely to be able to complete the 48 weeks of study treatment.
Have a history of pancreatitis (inflamed pancreas) or hepatitis within the last 6 months or any evidence of liver disease.
Have received an investigational vaccine within the past 3 months or have received gene therapy.
Have a severe medical condition such as diabetes or heart trouble.
Have been diagnosed with AIDS.
Have had radiation therapy or chemotherapy within 30 days of study entry, except for treatment of Kaposi's sarcoma.
Are taking medications that affect the immune system within 30 days of study entry.
Are taking medications that may interact with the study drugs.

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00004852

Show 66 Study Locations

Sponsors and Collaborators

Glaxo Wellcome

More Information

No publications provided

Study ID Numbers:	225D, EPV2000 1
Study First Received:	March 2, 2000
Last Updated:	June 23, 2005
ClinicalTrials.gov Identifier:	NCT00004852 History of Changes
Health Authority:	United States: Food and Drug Administration

Keywords provided by NIH AIDS Clinical Trials Information Service:

HIV-1
Drug Therapy, Combination
Zidovudine
Drug Administration Schedule
Lamivudine
Genotype

Phenotype
Reverse Transcriptase Inhibitors
Anti-HIV Agents
Viral Load
efavirenz

Additional relevant MeSH terms:

Antimetabolites
Anti-Infective Agents
Communicable Diseases
Sexually Transmitted Diseases, Viral
Slow Virus Diseases
Molecular Mechanisms of Pharmacological Action
Zidovudine
Lamivudine
Infection
Reverse Transcriptase Inhibitors
Anti-Retroviral Agents
Therapeutic Uses
Retroviridae Infections
Nucleic Acid Synthesis Inhibitors

Efavirenz
RNA Virus Infections
Anti-HIV Agents
Immune System Diseases
Acquired Immunodeficiency Syndrome
Enzyme Inhibitors
Antiviral Agents
Immunologic Deficiency Syndromes
Pharmacologic Actions
Virus Diseases
HIV Infections
Sexually Transmitted Diseases
Lentivirus Infections

ClinicalTrials.gov processed this record on November 27, 2009